Dr Reddys Laboratories (RDY) Net Cash Flow (2009 - 2026)

Dr Reddys Laboratories has reported Net Cash Flow for 18 years, with the latest figure at -$44.4 million in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 34.03% year-over-year to -$44.4 million in Q2 2026; TTM through Jun 2026 was $128.0 million, a 285.11% increase from a year earlier, with the FY2026 full-year figure at -$5.3 million, down 106.24% from the prior year.
• Net Cash Flow was -$44.4 million for Q2 2026 at Dr Reddys Laboratories, down from $77.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $87.3 million in Q4 2025, with the low at -$117.6 million in Q2 2022.
• Average Net Cash Flow over 5 years is -$9.7 million, with a median of -$4.6 million recorded in 2023.
• The largest YoY upside for Net Cash Flow was 1149.78% in 2025 against a maximum downside of 1847.09% in 2025.
• Over 5 years, Net Cash Flow stood at -$31.3 million in 2022, then plunged by 136.66% to -$74.0 million in 2023, then surged by 109.44% to $7.0 million in 2024, then surged by 1149.78% to $87.3 million in 2025, then slumped by 150.9% to -$44.4 million in 2026.
• The last three Net Cash Flow figures came in at -$44.4 million (Q2 2026), $77.0 million (Q1 2026), and $87.3 million (Q4 2025), per Business Quant data.